Global Lupus Therapeutic Market 2017-2021

Lupus therapeutic industry outlook

Market research analysts at Technavio predict that the global lupus therapeutic market will grow steadily at a CAGR of around 10% by 2021. This market research analysis identifies the high prevalence of lupus disease as one of the primary growth factors for this market. Lupus is one of the major autoimmune diseases associated with multiple symptoms such as pain, extreme fatigue, hair loss, cognitive issues, and physical impairments that disrupts every aspect of an individual's lives.

It has been observed that the American population is more prone to lupus disease with around 30% of world’s lupus cases registered in the Americas. Moreover, the diagnosis of lupus is highly challenging as there is no specific test for the diagnosis of lupus. This will, in turn, demand the effective treatment of this disease, in turn, fueling market growth.

Get A Free Sample

Lupus therapeutic market trends

One of the latest trends that will gain traction in the lupus therapeutic market is the adoption of inorganic growth strategies. Inorganic growth strategies such as M&A activities and industrial-academia collaborations for research will help in the growth of the companies and overall market growth. For instance, GlaxoSmithKline acquired Human Genome Sciences, the company that initially developed BENLYSTA, to enter lupus therapeutics market. These strategies can improve the pipeline of drugs for lupus treatment and assist in market penetration.

Moreover, these inorganic strategies can also help in the improvement of the research progress and industry-academia collaborations help to improve researches with a wider perspective. The coming years will witness a rise in the number of these inorganic strategies that will result in a strong research towards the development of better therapeutics for lupus disorders.

Lupus therapeutic market opportunity for key vendors  

The lupus therapeutic market is characterized by the presence of a large number of vendors. Factors such as a strong pipeline, new drug approvals, and inorganic growth strategies will intensify the level of competition among the market players.

The leading vendors in the lupus therapeutic market

• F.Hoffmann-La Roche
• GlaxoSmithKline
• Medlmmune
• Pfizer

Lupus therapeutic market segmentation by drug class

• Anti-inflammatory drugs
• Corticosteroids
• Immunosuppressant drugs
• Antimalarial drugs
• BLyS-specific inhibitors
• Biologicals

During 2016, the anti-inflammatory drugs segment accounted for the major shares of the lupus therapeutic market. However, the BLys-specific inhibitors segment will lead the market by 2021 due to the development of the Belimunab drug, which is the only approved drug for lupus disorder developed by GlaxoSmithKline.           

Lupus therapeutic market share by geographical segmentation

• Americas
• APAC
• EMEA

This market study estimates that in terms of geographic regions, the Americas will be the major revenue contributor to the market throughout the forecast period. The increasing occurrence of lupus disorders and advancements in the diagnosis drive the growth of the lupus therapeutic market in this region. Moreover, expected approvals of new drugs and strong diagnosis plans for lupus will also contribute to the growth of the market in the Americas. 

Want a bigger picture? Try a FREE sample of this report now!

See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from this report.   

Key questions answered in the report include

• What will the market size and the growth rate be in 2021?
• What are the key factors driving the global lupus therapeutic market?
• What are the key market trends impacting the growth of the global lupus therapeutic market?
• What are the challenges to market growth?
• Who are the key vendors in the global lupus therapeutic market?
• What are the market opportunities and threats faced by the vendors in the global lupus therapeutic market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global lupus therapeutic market?

Technavio also offers customization on reports based on specific client requirement.